Market Overview

Benzinga's Top Pre-Market Gainers

Related KYTH
CORRECTION: Kythera Reports FDA Acceptance of ATX-101 NDA, PDUFA Date Set at May 13, 2015
Kythera Reports FDA Acceptance of ATX-101 NDA, PDUFA Date Set at May 13, 2015
Related BCRX
BioCryst Receives Additional NIAID Funding For Manufacture and Development Of BCX4430, $19.9M Has Been Awarded To Date Under The Contract
Momentum Stocks Showing Weakness

Kythera Biopharmaceuticals (NASDAQ: KYTH) shares jumped 28.69% to $43.15 in pre-market trading after the company reported positive ATX-101 top line phase III trial results for the reduction of submental fat.

Huntsman (NYSE: HUN) surged 8.05% to $20.68 in the pre-market session after the company announced its plans to buy Rockwood Holdings' (NYSE: ROC) Performance Additives and Titanium Dioxide businesses for $1.1 billion in cash.

BioCryst Pharmaceuticals (NASDAQ: BCRX) shares gained 5.98% to $6.91 in the pre-market session after the company has been awarded contract by the National Institute of Allergy and Infectious Diseases to develop BCX4430 for the treatment of Marburg virus disease.

Discover Financial Services (NYSE: DFS) soared 4.92% to $54.43 in the pre-market trading. Discover Financial's PEG ratio is 1.26.

Posted-In: Top Pre-Market GainersNews Pre-Market Outlook Markets Movers

 

Related Articles (BCRX + DFS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters